Mega Genomics Limited (6667.HK)
HKSE · HKD · Healthcare · Diagnostics & Research
HK$7.09 (-0.70%) as of
Key statistics
- Market cap
- 1.57B
- P/E (TTM)
- 47.27
- EPS (TTM)
- 0.150
- Dividend yield
- 2.38%
- 52-week range
- 5.000 – 7.530
- Beta
- 0.76
- Revenue (TTM)
- 358.37M
- Profit margin
- 6.84%
- Volume
- 5.80k
About Mega Genomics Limited
Mega Genomics Limited, a genetic testing platform company, offers consumer genetic testing and cancer screening services in China. It offers brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer's disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson's disease risk assessment; full-scale cancer risk assessment packages; myocardial infarction and heart failure genetic testing; cardiovascular and cerebrovascular disease risk assessment packages; hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; cervical cancer genetic methylation testing, a cervical cancer test; telomere length genetic testing; and personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice. It also offers whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items; folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing for testing Alzheimer's disease; BRCA1/2 gene mutation testing kits; Alzheimer's disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits to health checkup centers and hospitals. The company was founded in 2016 and is headquartered in Beijing, China.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Beijing, China
- Employees
- 196
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.